Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials
Authors' conclusion
Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.
Study context
- Population
- Tirzepatide-treated participants with T2D in the SURPASS trials (FSG: SURPASS-1 to −4; weight: SURPASS-1 to −5)FSG n = 3,676
- Comparison
- Early vs nonearly responders to tirzepatide
- Primary endpoint
- Metabolic outcomes (change from baseline in efficacy parameters) by early glycemic or weight response
- Follow-up
- Week 40/42
Methodological detailspooled data across trials
- Pooled data across trials
Primary result
As reported in the abstract
HbA1c change, early vs nonearly responders in FSG
−2.6% vs. −2.0%
HbA1c change, early vs nonearly responders in weight
−2.5% vs. −2.2%
Weight change, early vs nonearly responders in FSG
−11% vs. −10%
Weight change, early vs nonearly responders in weight
−15% vs. −8%
Further findings
Proportion of early responders
- Early responders in FSG
- 50%
- Early responders in weight
- 31%
Safety
- Gastrointestinal (GI) adverse events (AEs) (generally mild to moderate) decreased over time and were in general comparable between early and nonearly responders
Original publication
Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials. Diabetes Care. Published 18 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →